Metformin, a commonly used hypoglycemic agent, inhibits ubiquitination modification of STING through an AXIN1-dependent mechanism and then enhances the antitumor efficacy of STK11-mutant lung cancer against PD-1 inhibitors (Wang et al., 2022c) (Figure 2). The gene discussed is STING1; the disease is lung carcinoma.